---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-009202"
form_type: "8-K"
ticker: "PRPH"
cik: "0000868278"
company_name: "ProPhase Labs, Inc."
filed_at: "2023-03-28T23:59:59+00:00"
generated_at: "2026-06-17T14:08:08.313926+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# ProPhase Labs reports record FY2022 revenue of $122.6M (+55% YoY), net income $18.5M

## Summary
- Revenue $122.6M vs $79.0M in 2021 (+55%); net income $18.5M ($1.17 diluted) vs $6.3M ($0.41).
- Adjusted EBITDA $38.6M vs $18.1M; includes $5.9M bad debt write-off from HRSA policy change.
- Cash & equivalents $9.1M, working capital $44.8M; paid $9.3M dividends, repurchased 1.3M shares for $11.3M.
- Subsequent to year-end: acquired exclusive worldwide rights to BE-Smart esophageal cancer test; Board authorized new $6M stock buyback.
- Management expects COVID-19 testing to slow but sees growth in Pharmaloz, Nebula Genomics, and BE-Smart test.

## SEC filing metadata
- accession: 0001493152-23-009202
- form_type: 8-K
- ticker: PRPH
- cik: 0000868278
- company_name: ProPhase Labs, Inc.
- filed_at: 2023-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/868278/000149315223009202/0001493152-23-009202-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/868278/000149315223009202/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-009202
- JSON: https://secwatch.observer/filing/0001493152-23-009202.json
- Plain text: https://secwatch.observer/filing/0001493152-23-009202.txt

## Key facts
- Earnings Releases
  ProPhase Labs, Inc. reported the year ended December 31, 2022 results: revenue $122.6 million, net income $18.5 million, EPS $1.17 per diluted share.
  - Period: the year ended December 31, 2022
  - Revenue: $122.6 million
  - Net income: $18.5 million
  - EPS: $1.17 per diluted share
  - Result: reported results
  source text: Financial highlights for the full year ended December 31, 2022, include the following: ● Net revenue of $122.6 million for the year ended December 31, 2022, as compared to $79.0 million for the year ended December 31, 2021, an increase of approximately 55%. ● Net Income of $18.5 million, or $1.17 per diluted share, for the year ended December 31, 2022, as compared to net income of $6.3 million, or $0.41 per share, for the year ended December 31, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/868278/000149315223009202/0001493152-23-009202-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.